Brepocitinib in Active PsA Brepocitinib is a novel tyrosine kinase 2/JAK1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks. https://t.co/qzOVsLMkYe https://t.co/ouLyB131r8